Figures
Abstract
Vancomycin-resistant Enterococci (VRE) are major pathogens causing nosocomial infections globally. This study investigated the genetic characteristics of vancomycin-resistant Enterococcus faecium (VREfm) in Thailand between June and November 2022. Fifty-two clinical VREfm isolates from Bangkok hospitals were analyzed for antimicrobial susceptibility, resistance genes, virulence factors, and genotypes using multilocus sequence typing (MLST). Phylogenetic analysis and goeBURST assessed genetic relationships and population structure. The VRE detection rate was 14.5%, with 97.1% E. faecium and 2.9% E. faecalis, likely reflecting the impact of an active case-finding program. All isolates exhibited resistance to penicillin, ampicillin, vancomycin, levofloxacin, ciprofloxacin, and rifampin. Resistance to erythromycin, high-level streptomycin, teicoplanin, and tetracycline occurred in 98.1%, 53.8%, 51.9%, and 17.3% of isolates, respectively. Chloramphenicol, linezolid, and high-level gentamicin remained effective against all isolates. The vanA gene was the sole resistance determinant detected. Virulence genes esp and hyl were present in 100% and 88.5% of isolates, respectively. MLST identified five sequence types (STs), with ST17 (86.5%) as the dominant lineage, followed by ST262 (7.7%), ST202, ST787, and ST80 (1.9% each). All isolates belonged to Clonal Complex 17. Genome analysis revealed various resistance genes (VanHAX, aac(6')-Ii, aad(6), ant(6)-Ia, msrC, and tetM) and virulence factors (acm, bopD, cpsA/uppS, cpsB/cdsA, ebpA, ebpB, ebpC, efaA, esp, sgrA, and srtC). The vanA gene primarily drives vancomycin resistance in Thailand’s VREfm. Genome analysis reveals antibiotic resistance genes, virulence factors, and mobile genetic elements that may drive antimicrobial resistance, increase diversity, and support adaptation in hospital settings. Ongoing infection control and active surveillance are essential.
Citation: Wongsuk T, Homkaew A, Oonanant W, Phumisantiphong U, Nutalai D, Utaranark P, et al. (2026) Molecular insights into antimicrobial resistance and virulence in hospital-associated of vancomycin-resistant Enterococcus faecium isolates in a tertiary hospital in Bangkok Thailand. PLoS One 21(3): e0343967. https://doi.org/10.1371/journal.pone.0343967
Editor: Mabel Kamweli Aworh, Fayetteville State University, UNITED STATES OF AMERICA
Received: December 2, 2025; Accepted: February 14, 2026; Published: March 24, 2026
Copyright: © 2026 Wongsuk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The assembled genomic sequence from this study was deposited in the NCBI Genbank Database under the Bioproject accession number PRJNA1207455. The accessions JBKKKC000000000.1, JBKKKD000000000.1, JBKKKE000000000.1, JBKKKF000000000.1, JBKKKG000000000.1, and JBKKKH000000000.1 correspond to G239, G293, G1101, G1176, G384, and G1768, respectively.
Funding: This study was funded by the Korea Foundation for Advanced Studies’s Asia Research Center, Institute of Asian Studies, Chulalongkorn University (grant number 009/2566.) to Dr Siriphan Boonsilp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Enterococci are facultative anaerobic Gram-positive cocci that naturally inhabit the gastrointestinal tract of humans and other animals. They can act as opportunistic pathogens under certain conditions, causing various infections, particularly in immunocompromised individuals and in hospital settings. The genus Enterococcus includes species such as Enterococcus faecalis and E. faecium, which are responsible for most human infections. Enterococci can cause urinary tract infections (UTIs), bacteremia, endocarditis, and intra-abdominal infections. They are a leading cause of hospital-acquired infections, including catheter-associated UTIs and surgical site infections [1,2].
Enterococcus has high pathogenic potential because of the presence of virulence factors that facilitate colonization, persistence, and immune evasion. The key virulence genes in Enterococcus include asa (aggregation substance), gel (gelatinase), cyt (cytolysin), esp (enterococcal surface protein), hyl (hyaluronidase), cpd (sex pheromone determinant), and ebp (endocarditis and biofilm-associated pilus subunit A) [3–5]. Compared with E. faecalis, E. faecium can develop multidrug resistance and is tolerant to various antibiotics, including aminoglycoside, ampicillin, and vancomycin [6,7]. The synergistic interaction between antimicrobial resistance and virulence is central to the clinical impact of vancomycin-resistant Enterococcus faecium (VREfm). Strains that harbor both multidrug resistance determinants and major virulence factors pose a substantially greater public health threat than resistant strains with limited virulence, because they are simultaneously difficult to treat and highly capable of colonization, transmission, and invasion [8,9]. In VREfm, the coexistence of resistance genes such as vanA, aminoglycoside- and tetracycline-resistance determinants with key virulence factors including esp and hyl, as well as multiple adhesins (e.g., acm, efaA) and biofilm-associated loci (ebp operon), enhances persistence in the hospital environment and promotes host colonization [10].
The emergence of vancomycin-resistant Enterococcus (VRE) is particularly concerning because of van genes such as vanA, vanB, and vanC. These genes encode enzymes that modify d-alanyl-d-alanine to d-alanyl-d-lactate or d-alanyl-d-serine, significantly reducing vancomycin binding affinity [11–13]. VRE have spread worldwide because of their multidrug resistance. The World Health Organization has specified VRE as a priority for developing new drugs [14]. In many countries, the prevalence of VRE has significantly increased. In Germany, the percentage of vancomycin-resistant Enterococcus faecium (VREfm) has increased from <5% in 2001 to 14.5% in 2013 [15]. The European Antimicrobial Resistance Surveillance Network reported an increase in the VRE rate from 10.4% in 2014 to 17.3% in 2018 [16]. According to Thailand’s National Antimicrobial Resistance Surveillance Center, the frequency of VRE increased from 2.8% in 2015 to 8.1% in 2023. (Thailand National Antimicrobial Resistance Surveillance Center, 2025) [17]
VRE have significant implications for infection control in healthcare settings because of their association with outbreaks and their ability to transfer resistance genes to other pathogens. Understanding the virulence factors for the circulation of VRE strains within hospitals provides insights into the pathogenic potential and severity of infections caused by these strains, thereby enabling better assessment of the ongoing outbreak trends in the area. In Thailand, studies on the molecular characteristics of E. faecium are limited, and data on the prevalence of virulence factors are lacking. Therefore, this study aimed to provide a detailed molecular characterization of hospital-associated VRE E. faecium isolates from a tertiary hospital in Bangkok, Thailand. Specifically, we sought to: (i) determine the phenotypic antimicrobial susceptibility profiles of the isolates; (ii) identify the genetic determinants of vancomycin resistance (e.g., vanA and vanB genes); and (iii) evaluate the prevalence of key virulence markers associated with clinical severity and biofilm formation.
Materials & methods
Study setting
This study was conducted at Vajira Hospital, a public tertiary-care teaching hospital in Bangkok, Thailand, with approximately 740 inpatient beds. As a major referral center for complex medical and surgical cases, the hospital includes high-risk units such as internal medicine, surgery, and intensive care, where high antibiotic pressure and vulnerable patient populations facilitate the emergence and transmission of VREfm. The hospital has implemented active case-finding surveillance for VRE, routinely screening high-risk patients to identify colonization and prevent nosocomial spread. This practice increases the detection of VRE, including both infected and colonized patients. Although routine culture and phenotypic susceptibility testing are well established, systematic molecular characterization of VRE has been limited and circulating clones may be underrecognized. Therefore, this study was specifically designed to perform molecular characterization of VREfm isolates detected through active surveillance and clinical cultures, providing essential baseline genomic data to support future antimicrobial resistance surveillance, infection control, and antimicrobial stewardship efforts.
Study design
A cross-sectional study with data collected retrospectively was conducted at a tertiary care hospital in Bangkok, Thailand. Clinical isolates were consecutively collected from patients admitted to Vajira Hospital between 13/06/2022 and 30/11/2022. Bacterial collection was obtained from leftover cultures generated during routine diagnostic laboratory work. Data were accessed for research purposes on 18/02/2023. The Institutional Review Board committee approved this study, and patient consent was waived due to its use of leftover specimens and deidentified samples. This study was approved by The Institutional Review Board of Faculty of Medicine of Vajira Hospital, Navamindradhiraj University (COA 010/2566).
VREfm screening and identification
Bacterial isolates were collected and identified according to the routine clinical bacteriology guidelines. The isolates originated from clinical specimens, including urine, blood, pus, and stool, collected from both outpatients and inpatients. All enterococcal isolates were incubated overnight on sheep blood agar at 37°C and were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Microflex, Bremen, Germany). VREfm was preliminarily screened using the antibiotic disk diffusion technique for seven antibiotics including ampicillin (10 µg), erythromycin (15 µg), linezolid (30 µg), teicoplanin (30 µg), vancomycin (30 µg), tetracycline (30 µg), and gentamicin (120 µg). The VREfm isolates were selected for further microbroth dilution to test antimicrobial susceptibility.
Antimicrobial susceptibility testing
All VREfm isolates (n = 52) were tested for antimicrobial susceptibility using the Sensititre® microbroth dilution system according to the manufacturer’s instructions. Overnight cultures were transferred to sterile water to achieve a 0.5 McFarland standard. Then, 30 μL of each suspension was transferred to sterile cation-adjusted Mueller–Hinton broth, and 50 μL of the broth solution was dispensed into Sensititre™ THAPF (Trek Diagnostic Systems). Minimal inhibitory concentration (MIC) plates that included the following antibiotics (range of concentrations in μg/mL) were used: vancomycin (0.25–32 μg/mL), teicoplanin (4–32 μg/mL), penicillin (0.06–8 μg/mL), rifampin (1–4 μg/mL), ampicillin (0.12–8 μg/mL), erythromycin (0.25–4 μg/mL), levofloxacin (0.25–8 μg/mL), daptomycin (0.5–4 μg/mL), linezolid (0.5–8 μg/mL), chloramphenicol (8–16 μg/mL), tetracycline (2–16 μg/mL), gentamicin (500 μg/mL), ciprofloxacin (0.5–4 μg/mL), and streptomycin (1,000 μg/mL). E. faecalis ATCC 29212, E. faecalis ATCC 51299, and S. aureus ATCC 29213 were used as quality control strains. The MICs were recorded as the lowest concentration of an antimicrobial that completely inhibited bacterial growth (M100 33rd CLSI,2023). Resistance breakpoints published by the Clinical and Laboratory Standards Institute were used (M100 33rd CLSI, 2023). Multidrug resistance was defined as resistance to two or more classes of antibiotics. The breakpoints for vancomycin susceptibility were ≤4 μg/mL for “susceptible,” 8–16 μg/mL for “intermediate resistance,” and ≥32 μg/mL for “resistant.” Strains with vancomycin MICs of ≥32 μg/mL were regarded as VRE. This study was limited by the upper concentration of vancomycin tested in the Sensititre™ THAPF panel, which capped MIC determination at 32 µg/mL. The exact MIC values beyond this threshold could not be determined.
DNA extraction
Genomic DNA was extracted using 10% Chelex solution in 0.1% Triton X-100 and 10-mM Tris buffer (pH 8.0). Then, 200 µL of 10% Chelex solution was added to each bacterial cell pellet. The mixture was vortexed for 10 s, heated at 95°C for 20 min, and centrifuged at 10,000 × g for 20 s. The supernatant was used as the substrate for polymerase chain reaction (PCR).
Detection of antimicrobial resistance and virulence genes
Eight antimicrobial resistance genes (i.e., vanA, vanB, aac, aph(3')-IIIa, ant(6)-Ia', tetL, tetO, and tetM) and eight virulence genes (i.e., asa, gel, esp, hyl, cpd, ebp, pai, and sprE) were detected using PCR using the primers and amplification conditions detailed in S1 Table. PCR was performed using FIREPol Master Mix Ready to Load (Solis Biodyne) following the manufacturer’s instructions. PCR was performed in a reaction volume of 20 µL PCR reaction mixture containing 0.8 µM of each primer and 20 µL of 5 × FIREPol Master Mix Ready to Load (Solis Biodyne) containing buffer, nucleotides, and Taq polymerase. All reactions were run on a T100 Thermal Cycler (Bio-Rad Laboratories Inc, Hercules, CA, USA). E. faecalis ATCC 51299 was used as a positive control for vanB, asa, gel, esp, cpd, ebp, pai, sprE, aph(3')-IIIa, and ant(6)-Ia. The expression of virulence and resistance genes was confirmed by DNA sequencing.
Genotyping and phylogenetic tree construction
All VREfm isolates were genotyped using MLST as previously published for E. faecium. Seven gene fragments were used for typing: atpA, ddl, gdh, purK, gyd, pstS, and adk. PCR was performed using Kit PCR 5 × FIREPol Master Mix Ready to Load (Solis Biodyne) according to the manufacturer’s instructions. S1 Table lists the primers used for the amplification of fragment genes. All DNA fragments were sequenced (U2Bio Sequencing Service, Korea) in both directions using amplification primers. DNASTAR Lasergene was used to align and edit the DNA sequences. The consensus sequences of the seven loci were determined for all isolates. The consensus sequences of each locus of all isolates were submitted to the MLST database to define the allele profile and sequence type (ST). The population structures were analyzed using the goeBURST algorithm with Phyloviz.
Each sequence of the seven genes was trimmed to the correct length with its start and end nucleotides. Sequences were concatenated in the order of atpA, ddl, gdh, purK, gyd, pstS, and adk. The best evolutionary model for concatenated datasets was selected using the Bayesian Information Criterion (BIC) in MEGA-X. The model with the lowest BIC score was chosen as the basis for constructing. Initial tree for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The phylogenetic trees was constructed using the maximum likelihood method. Bootstrap analysis was conducted using 1,000 replicates.
Whole-genome sequencing (WGS) and data analysis
Six representative isolates with different STs were selected for WGS. The genomic DNA was isolated using phenol-chloroform extraction. In brief, a loop of bacterial colonies was transferred to a 1.5 ml microcentrifuge tube and frozen at −20°C for 1 hour. Five hundred microliter of lysis buffer containing 0.5 g sodium dodecyl sulfate, 1.4 g NaCl, 0.73 g EDTA, and 20 mL of 1 M Tris–HCl per 100 mL lysis buffer was added. Then, add 5 μL of 2-mercaptoethanol. The suspension was vortexed and incubated at 65°C for one hour. The lysate was extracted with 500 μL of phenol–chloroform–isoamyl alcohol (25:24:1, v:v:v) and mixed by pipetting. The tubes were centrifuged for 5 min at 12,500 rpm at 4°C. The aqueous phase was transferred to a fresh tube, and DNA was precipitated with 500 μL of isopropanol and incubated at 4°C for 1 hour. The mixture was centrifuged at 12,500 rpm for 5 minutes at 4°C to pellet the DNA. The DNA pellet was washed with 70% ethanol, centrifuged for 5 minutes at 12,500 rpm, and air dried. The DNA was resuspended in 100 μL sterile deionized water and kept at −20°C.
WGS was conducted using a short-read, paired-end sequencing strategy on the Illumina Nextseq550 platform at CELEMICS (Celemics, Inc., Seoul, Korea), in collaboration with U2Bio (Thailand) Co., Ltd. (Bangkok, Thailand). The sequencing reads were trimmed and filtered using AfterQC (version 0.9.6). De novo genome assembly was performed using Unicycler (version 0.5.0), and the quality of the assembled genomes was assessed using QUAST (version 5.0.2). Genome completeness and contamination were estimated using CheckM (version 1.1). The assembled genomes were annotated using Prokka (version 1.14.6). Taxonomy based on the genomes was determined using the Type (Strain) Genome Server (https://tygs.dsmz.de/). The sequencing reads were trimmed and filtered using AfterQC (version 0.9.6). cgMLST were carried out using established typing schemes in MBioSEQ Ridom Typer. version 11.1. Antibiotic resistance genes were identified based on the Comprehensive Antibiotic Resistance Database [18] and ResFinder4.1 [19]. Plasmid replicons and mobile genetic elements were analyzed using PlasmidFinder2.1 [20] and MobileElementFinder [21]. Virulence genes were predicted using VirulenceFinder2.0 [22] and the virulence factor database (http://www.mgc.ac.cn/VFs/).
Statistical analysis
Descriptive statistical analyses were performed using IBM SPSS Statistics 30.0 for Windows (IBM Corp., Armonk, NY, USA). Frequencies and percentages were calculated to describe the distribution of virulence genes, antimicrobial resistance genes, and genotypes, including sequence types and cgMLST complex types, among the isolates.
Results
Species distribution of Enterococcus spp.
From the clinical isolates collected from patients treated at Vajira Hospital between 13th June 2022 and 30th November 2022, a total of 8,187 patients underwent laboratory testing. Enterococcus spp. were identified in 470 cases, yielding an overall detection rate of 5.74%. The most commonly isolated Enterococcus species was E. faecalis (271, 57.7%), followed by E. faecium (180, 38.3%), E. raffinosus (8, 1.7%), E. gallinarum (5, 1.1%), E. hirae (3, 0.6%), E. casseliflavus (2, 0.43%), and E. cecorum (1, 0.2%). Phenotypic testing revealed vancomycin-resistant Enterococcus (VRE) in 68 of the 470 isolates, corresponding to an overall VRE detection of 14.5%. Among these, 97.1% (66/68) were identified as E. faecium (VREfm), and 2.9% (2/68) as E. faecalis. Accordingly, vancomycin resistance was identified in 36.7% (66/180) of E. faecium isolates and only 0.7% (2/271) of E. faecalis isolates. In this study, 52 VREfm isolates were recovered for further analysis; 75% (39/52) were recovered from urine samples, followed by fecal specimens (15.4%, 8/52), wound exudates (5.8%, 3/52), and one isolate each (1.9%) from blood and bile.
Antimicrobial susceptibility pattern of VREfm
The antibiotic susceptibility of all 52 VREfm clinical isolates was analyzed (Table 1). All isolates exhibited dose-dependent susceptibility to daptomycin; resistance to penicillin, ampicillin, vancomycin, ciprofloxacin, levofloxacin, and rifampin; and sensitivity to chloramphenicol, linezolid, and high-level gentamicin (HLG) (MIC > 500 µg/mL). Resistance to erythromycin, teicoplanin, and tetracycline was observed in 51 (98.1%), 27 (51.9%), and 9 (17.3%) isolates, respectively. High-level streptomycin resistance (HLSR) with MIC > 1,000 µg/mL was observed in 28 (53.8%) isolates. Table 2 presents the antibiotic resistance patterns of the VREfm isolates; 11 antibiotic resistance patterns were recorded. All VREfm isolates were resistant to at least four categories of antibiotics, with 51 (98.1%) isolates being resistant to ≥5 antibiotics (Table 2).
Antibiotic-resistant gene identification
All VREfm strains (100%) harbored the vanA gene, whereas the vanB gene was not detected in any isolate. The prevalence of tetracycline-resistant genes in the VREfm isolates was as follows: tetM was detected in 28 of the 52 isolates, exhibiting the highest rate of occurrence among tet genes at 53.9% (28/52). The frequency of tetL and tetO was 13.5% (7/52) and 3.9% (2/52), respectively. Among the nine phenotypically tetracycline-resistant VREfm isolates, 77.8% (7/9), 55.6% (5/9), and 22.2% (2/9) contained tetM, tetL, and tetO, respectively. tetM was detected simultaneously along with tetL and tetO in 55.6% (5/9) and 11.1% (1/9) of the isolates, respectively. High-level aminoglycoside-resistant genes were observed in 53.9% (28/52) of the isolates for ant(6)-Ia, 53.9% (28/52) for aph(3')-IIIa, and 11.5% (6/52) for aac(6’)-Ie-aph(2")-Ia. Among the 28 phenotypically HLSR VREfm isolates, 89.3% (25/28) had ant(6)-Ia, 82.1% (23/28) had aph(3')-IIIa, and 7.1% (7/28) had aac(6')-Ie-aph(2")-Ia. Concurrent ant(6)-Ia and aph(3')-IIIa were observed in 82.1% (23/28) of the isolates. The simultaneous presence of ant(6)-Ia and aac(6')-Ie-aph(2")-Ia was detected in 7.1% (2/28) of the isolates (Table 3 and Fig 1).
Colored blocks represent the presence of genes, and gray blocks represent the absence of genes. The rows represent isolates, and the columns represent genes involved in antimicrobial resistance and virulence factors.
A correlation between sequence types and antibiotic resistance genes revealed ST-specific patterns, with ST17 isolates most commonly carrying aph(3')-IIIa, ant(6)-Ia', and tetM. ST262 and ST787 exhibited broader resistance genes, including aac(6')-Ie-aph(2")-Ia, aph(3')-IIIa, ant(6)-Ia', tetL, and tetM. The presence of ST-specific resistance gene patterns, with ST262 and ST787 representing a potential for multidrug resistance and therapeutic failure. ST202 harbored aac(6')-Ie-aph(2")-Ia, tetL, and tetM, but lacked aph(3')-IIIa, ant(6)-Ia'. ST80 carried aph(3')-IIIa, and ant(6)-Ia'. (Fig 1).
Resistance gene and specimen Correlation; urine isolates represented the majority of samples and exhibited the greatest variability in antibiotic resistance genes, likely due to the larger sample size. Among the 39 urine isolates, aph(3')-IIIa was detected in 20 isolates (51.3%), ant(6)-Ia in 21 (53.8%), and tetM in 19 (48.7%). The tetL gene was found exclusively in four ST262 isolates (10.3%). The tetO gene was detected in only one ST17 isolate. Notably, four urine isolates (10.3%) carried the high-level aminoglycoside resistance gene aac(6')-Ie-aph(2")-Ia, including two ST262 isolates, one ST17, and one ST202. Stool isolates (n = 8) generally harbored a narrower resistance profile, with aph(3')-IIIa and ant(6)-Ia each detected in four isolates (50%), tetM in four (50%), and tetL in one (12.5%). Neither aac(6')-Ie-aph(2")-Ia nor tetO was detected in stool isolates. Pus isolates demonstrated broader resistance profiles, with detection of 66.67% aac(6’)-Ie-aph(2")-Ia, 66.67% aph(3')-IIIa, 33.33% ant(6)-Ia, 33.33% tetL, 100% tetM, and 33.33% tetO. The single blood isolate harbored all major resistance genes, including aph(3')-IIIa, ant(6)-Ia, tetL, and tetM. The bile isolate exhibited a limited profile, carrying aph(3')-IIIa, ant(6)-Ia, and tetM.
Virulence gene identification
Eight virulence genes—asa1, gelE, esp, hyl, cpd, ebp, pain, and sprE—were tested to determine which enterococcal virulence factor was present in the clinical VREfm isolates. asa1, gelE, cpd, esp, pain, and sprE were absent in all isolates, whereas esp was present in all isolates, and hyl was detected in 88% (46/52) of the isolates. The percentage of VREfm isolates carrying the esp+ and hyl+ genes (88%, 46/52) was higher than that of VREfm isolates carrying the esp+ gene alone (13.5%) (Table 3 and Fig 1).
Genotypic classification of VRE strains using MLST
Among the 52 VREfm isolates, five STs were identified: ST17, ST80, ST202, ST262, and ST787. The predominant strain identified within the hospital under study was ST17, accounting for 86.54% (45/52) of the isolates, followed by ST262 (7.69%, 4/52), ST787 (1.92%, 1/52), ST80 (1.92%, 1/52), and ST202 (1.92%, 1/52) (Fig 1). All isolates belonged to the same ancestral lineage and were classified under Clonal Complex (CC) 17. Fig 2 presents the goeBURST network diagram of CC17, illustrating the relationships between the STs using Phyloviz 2.0. From the analysis, ST17 was identified as the primary founder because of its highest frequency. ST202 was the closest relative to ST17, with a single-locus variant, followed by ST80, which exhibits a double-locus variant. In contrast, ST262 and ST787 exhibited a triple-locus variant. Notably, ST787 was closely connected to ST80 within the network (Fig 2). Evolutionary analyses of seven concatenated sequences were conducted using MEGA-X. Hasegawa-Kishino-Yano model. The BIC score was 11110.06999. Then, a phylogenetic tree was constructed using the maximum likelihood method based on the HKY model with 1,000 replicates in bootstrap analysis. The tree with the highest log likelihood (−4919.79) is presented. This analysis involved 52 nucleotide sequences. The first, second, third, and non-coding codon positions were included. The final dataset included 3,458 positions.; S1Fig shows the resulting phylogenetic tree. The relationships observed were as follows: ST17 was most closely related to ST202, followed by ST262, ST80, and ST787.
The diagram illustrates the genetic relationships among E. faecium sequence types (STs) identified through MLST. Each node (numbered box) represents a unique ST, and the size of each box is proportional to the number of isolates corresponding to that ST in the global MLST database. Solid lines connect STs that are single-locus variants (SLVs), indicating close genetic relatedness. STs identified in this study are indicated with arrows. A total of 52 vancomycin-resistant E. faecium (VREfm) isolates were analyzed, and five distinct STs were detected. These were categorized into three groups based on their genetic clustering: Group 1: ST17 and ST202, with ST17 serving as the central (founder) ST within the group, suggesting it may be the ancestral type. Group 2: ST80 and ST787, which clustered closely together and formed a distinct subgroup. Group 3: ST262, which did not group with other STs and thus constituted a separate lineage.
Genome characteristics
To characterize the genome of VREfm circulating in our hospital, six VREfm representative isolates were selected for WGS based on different STs, including G239 (ST262), G293 (ST787), G384 (ST17), G1101(ST80), G1176 (ST202), and G1768 (ST17). S2 Table presents an overview of the genome and assembly characteristics of the VREfm sequences. The total assembled genome size ranged from 2.8 to 3.0 MB, the GC content ranged from 37.48 to 37.75. S2 Table also presents the total number of contigs.
Core genome multilocus sequence typing (cgMLST) was applied to six representative vancomycin-resistant Enterococcus faecium (VREfm) genomes belonging to five different sequence types (STs), including ST262 (G239), ST787 (G293), ST80 (G1101), ST202 (G1176), and ST17 (G384 and G1768). cgMLST analysis further assigned the six isolates to distinct complex types (CTs): CT7004-ST262 (G239), CT10028-ST787 (G293), CT10025-ST80 (G1101), CT10026-ST202 (G1176), CT10029-ST17 (G384), and CT10027-ST17 (G1768). Among these, one previously described CT (CT7004) and five novel CTs were identified. Two isolates (G384 and G1768) belonged to ST17; cgMLST distinguished them into two separate CTs (CT10029 and CT10027, respectively), demonstrating the higher discriminatory power of cgMLST compared with conventional MLST for differentiating closely related VREfm strains.
Using VFanalyzer and Virulence Finder to predict virulence-associated genes, 14 virulence genes were detected (Table 4). The virulence genes present in the VREfm genome included adhesin (acm, ebpA, ebpB, ebpC, srtC, ecbA, efaA, esp, scm, sgrA), capsule-associated antiphagocytosis (cpsA/uppS, cpsB/cdsA), biofilm formation (bopD), and hyaluronidase enzyme (hylE) (Table 4).
Antimicrobial resistance genes conferring resistance to six antimicrobial classes were detected among six representative VREfm genomes. Genes encoding resistance to tetracyclines [tetM and tetL], macrolides [ermB, ermT, msrC, and efmA], aminoglycosides [aac(6')-Ii, aph(3')-III, ant(6)-Ia, aac(6')-aph(2"), aph(2")-Ia, aad(6), and SAT-4], phosphonic acid (FosXCC and FosI), trimethoprim (dfrG and dfrF), and glycopeptide (VanHAX) were detected among the six isolates. Tetracycline resistance was mediated mainly by the tetM gene in all TET-resistant isolates (i.e., G239, G293, G384, G1176, and G1768) (Table 4).
Plasmid sequence analysis using PlasmidFinder revealed ten plasmid-associated replication genes (i.e., rep11a, rep18b, rep22, repUS15, repUS43, rep1, rep2, rep17, repUS7, and rep14a). All six isolates had at least five plasmid replicons in their genome. rep11a and repUS15 were the most common replicon types in all six isolates, followed by rep18b, rep17, and rep2 in four isolates; rep22 in three isolates; repUS43, rep1, and repUS7 in two isolates; and rep14a, rep11a, repUS15, rep2, and rep17 in one isolate, which occurred in the same four isolates. repUS43 coexisted with tetM and tetL on the same contig on the G293 (ST787) genome (Table 3).
Using the Mobile Element Finder tool, six insertion sequence (IS) elements were identified. Among them, IS16 was the most prevalent IS element, appearing in all six genomes, followed by ISEfa5 and IS256 appearing in two isolates each and ISLgar5, ISEfa11, and ISEfm2 appearing in one isolate each. ISEfm2 was found alongside the msrC gene in the same contig in the G1176 (ST202) genome (Table 4).
Discussion
Enterococcus is a significant challenge in hospital-acquired infections, particularly in intensive care units. The bacteria can spread through person-to-person contact or contaminated medical equipment. Therefore, effective infection control measures to monitor and prevent the dissemination of Enterococcus within hospital settings are critical. In this study, E. faecalis was the most commonly isolated species (57.7%), followed by E. faecium (38.3%). However, vancomycin resistance was observed more frequently in E. faecium than in E. faecalis, consistent with the results of previous studies [23,24]. The van gene, a genetic determinant of vancomycin resistance, can be horizontally transferred among Enterococcus spp. [25]. In this study, all VREfm isolates carried the vanA gene, whereas no isolates contained the vanB gene, which is consistent with the results of previous studies in Thailand [26,27]. Urine samples accounted for most VRE isolates (75%), consistent with the findings from Songklanagarind Hospital, which reported the highest detection of VRE in urinary specimens [26]. This is unsurprising because Enterococcus is the second leading cause of UTIs after Escherichia coli. The overall detection rate of vancomycin-resistant Enterococcus (VRE) was 14.5% among Enterococcus spp., while 36.7% of E. faecium isolates (VREfm) were found to be vancomycin-resistant. These rates are substantially higher than those reported by the Health Policy and Systems Research on Antimicrobial Resistance (HPSR-AMR) Network, which documented an increase in vancomycin resistance among Enterococcus spp. in Thailand from 6.0% in 2019 to 6.9% in 2023, and in E. faecium specifically from 7.6% to 15.7% during the same period (https://www.thaiamrwatch.net) [28]. Moreover, a study conducted in a hospitals in Thailand has reported lower and more variable VRE detection rates among Enterococcus spp., ranging from 0.2% to 4.3% [26]. The high VRE and VREfm detection rate observed in our hospital is likely attributable to the implementation of active surveillance programs. These programs systematically screen patients, particularly those in high-risk wards, for VRE colonization to prevent the transmission of nosocomial infections. Consequently, the VRE detection rate reported in this study does not accurately reflect the actual infection rate among hospitalized patients, but rather includes all VRE-positive findings from specimens submitted to the laboratory, encompassing both clinical infections and asymptomatic colonization (carriers). When compared to other countries in Asia, our observed VREfm rate (36.7%) also exceeds regional averages. A meta-analysis study reported a pooled vancomycin resistance rate of 8.1% among Enterococcus spp. Across Asia, with resistance in E. faecium reaching 22.4% [29]. Country-specific reports have documented VRE rates of 3.1% in East Asia (China), 7.7% in South Asia (India and Pakistan), and 11.4% in Western Asia (Iran, Saudi Arabia, Jordan, and Kuwait) [29]. In this context, the 36.7% VREfm detection rate in our study is significantly higher than both regional and global estimates. Overall, these findings highlight the critical need for ongoing surveillance of vancomycin-resistant Enterococcus (VRE), especially in healthcare settings that implement active screening measures. Although active surveillance facilitates prompt identification and helps reduce hospital-acquired transmission, it may also lead to an overestimation of prevalence by detecting both clinical infections and asymptomatic colonization. Therefore, it is essential to interpret surveillance data with caution, differentiating between actual infections and colonization, to support informed decisions regarding antimicrobial stewardship and infection prevention efforts.
VRE often exhibits multidrug resistance, limiting therapeutic options [30,31]. Antimicrobial susceptibility testing revealed that all isolates were resistant to β-lactams (ampicillin and penicillin), glycopeptides (vancomycin), fluoroquinolones (levofloxacin and ciprofloxacin), and ansamycin (rifampin). However, these isolates exhibited susceptibility to phenol (chloramphenicol), oxazolidinone (linezolid), and lipopeptide (daptomycin), suggesting that these three antibiotics are available for treating VRE-related infections. Linezolid remains the treatment of choice for VRE infections. In the literature, chloramphenicol effectively treats VRE bacteremia [32]. Resistance to the tetracycline class in Enterococcus is mediated by efflux pumps [tetK and tetL] and ribosomal protection proteins [tetM, tetO, tetS, tetT, and tetW] [33]. In this study, phenotypically tetracycline-resistant VREfm was detected in 17.3% of the isolated strains, and the genotypically tetracycline-resistant (tet) gene was observed in 53.9% of the isolated strains, including tetM in 53.9%, tetL) in 13.5%, and tetO in 3.9%. Fifty-five percent of the phenotypically tetracycline-resistant isolates concurrently harbored the tetL and tetM genes. The presence of both the tetL efflux pump and the tetM protection factor was found to be associated with resistance in clinical isolates of E. faecium [34]. The tetM gene, which is carried by conjugative transposons and mediates the ribosomal protection mechanism to prevent 23S rRNA binding, was mainly associated with tetracycline resistance in this study. A recent study found that the expression of two tetracycline resistance determinants, tetL and tetM, can confer tigecycline resistance in enterococcal clinical isolates [35]. Enterococcus intrinsically exhibit low-level aminoglycoside resistance, mostly because of the presence of the aac(6′)-Ii gene; however, high-level aminoglycoside resistance is mediated by the acquisition of aminoglycoside resistance genes, including aac(6′)-Ie–aph(2′′)-Ia, aph(3′)-IIIa, and ant(6)-Ia [36]. In this study, 53.8% of the VREfm isolates exhibited phenotypic HLSR. Furthermore, the VREfm isolates carried a gene associated with high-level aminoglycoside resistance, specifically aph(3′)-IIIa (53.9%), ant(6)-Ia (53.9%), and aac(6′)-Ie–aph(2′′)-Ia (11.5%). Eighty-two percent of the phenotypic HLSR isolates carried both aph(3′)-Ia and ant(6)-Ia. The correlation between specimen type and the distribution of antibiotic resistance genes in VREfm isolates demonstrates urine samples, which constituted the majority, showing the highest diversity of resistance genes, likely due to the larger sample size and selective antibiotic pressure in urinary tract infections. In contrast, stool isolates exhibited a more limited resistance profile. Pus and blood isolates carried broader resistance determinants, including genes associated with high-level aminoglycoside and tetracycline resistance, reflecting their clinical severity. These findings highlight the importance of specimen-specific surveillance and continuous genomic monitoring, alongside prudent antimicrobial stewardship, to effectively manage the spread and clinical impact of multidrug-resistant E. faecium in healthcare settings.
Pathogenicity-associated gene analysis revealed that 100% of the isolates carried the esp gene, and 88.5% carried the hyl gene. The high prevalence of esp is consistent with the findings of previous studies, demonstrating its common occurrence in uropathogenic E. faecium [26,37]. The 88.5% prevalence of hyl observed in this study is notably higher than the 5.6% reported in previous studies within the same country (16). These findings suggest that esp and hyl are major virulence factors in the strains under study. The esp gene contributes to bacterial adherence and biofilm formation in the urinary tract, whereas the hyl gene, which encodes hyaluronidase, facilitates colonization and tissue invasion.
The MLST analysis identified five STs associated with the hospital setting: ST17, ST80, ST202, ST262, and ST787. Among them, ST17 was the most frequently observed strain. Numerous studies have reported outbreaks of E. faecium ST17 and ST80 in various regions, including Germany [38], France [39], Australia [40], Thailand [27,41], and China [42]. ST262 has been linked to infections in South Korea [43], Europe [44], Cuba [45], and Russia [46]. ST202 has been associated with hospital-acquired infections in Norway [47], Germany [48], and China [49]. Furthermore, ST787 has been reported in South Korea, Sweden, Pakistan, Denmark, and Ireland (www.pubmlst.org), indicating that the identified STs, particularly ST17, ST80, ST202, ST262, and ST787, are globally distributed and associated with hospital-acquired infections. Notably, this study is the first to report the presence of VREfm ST202, and ST787 in Thailand, contributing new insights into the molecular epidemiology of VREfm in the region. The correlation between sequence types (STs) and antibiotic resistance genes revealed distinct ST-specific patterns of resistance. ST17, the most common lineage, predominantly carried aph(3')-IIIa, ant(6)-Ia, and tetM, reflecting a more conserved resistance profile. In contrast, ST262 and ST787 harbored a broader array of resistance genes, including aac(6')-Ie-aph(2")-Ia, indicating a higher potential for multidrug resistance and treatment failure. ST202 showed a unique resistance profile, lacking some aminoglycoside-modifying enzymes, while ST80 carried only aph(3')-IIIa and ant(6)-Ia. These findings highlight the value of ST-based resistance profiling in informing surveillance, antimicrobial stewardship, and infection control efforts. However, this ST-based analysis has limitations, as conventional MLST may lack sufficient resolution to distinguish closely related strains within the same lineage in a hospital setting. Therefore, small genetic differences and potential transmission relationships may not be fully identified without higher-resolution approaches, such as core genome multilocus sequence typing (cgMLST).
The genomic characterization of the six selected VREfm isolates allowed us to identify more details in the resistance and virulence genes of each representative ST strain. All six representative genomes contained resistance genes associated with three antimicrobial classes (aminoglycosides, glycopeptides, and macrolides). All VREfm isolates carried genes associated with vancomycin resistance, specifically the vanA gene cluster (i.e., vanR, vanS, vanH, vanX, vanY, and vanZ). All selected VREfm genomes carried the aac(6′)-Ii gene, which was previously reported to be associated with intrinsic resistance to low-level aminoglycosides in E. faecium [50]. The presence of the ant(6)-la gene, which is responsible for HLSR, was mainly associated with phenotypically identified high-level resistance. In terms of macrolide and lincosamide resistance determinants, in addition to msrC, which was intrinsically present in all selected VREfm isolates, other genes such as efmA, ermB, and/or ermA were discovered in phenotypically erythromycin-resistant strains. The VREfm isolates harbored tetM and/or tetL, which are commonly associated with tetracycline-resistant Enterococcus. Fosfomycin has shown good in vitro action against Enterococci, including VRE strains, and is used to treat uncomplicated UTIs [51–53]. In our study, the fosXCC and fosI genes associated with fosfomycin resistance were detected in isolates G239-ST262-CT7004, G1176-ST202-CT10026, and G1768-ST17-CT10027. Consistent with these genotypic findings, fosfomycin disk-diffusion testing showed resistance in G239-ST262-CT7004 and G1768-ST17-CT10027, while G1176-ST202-CT10026 exhibited intermediate susceptibility. Overall, these results demonstrate a clear genotype–phenotype correlation, as the presence of fosXCC/fosI was associated with resistant or reduced susceptibility to fosfomycin. A study from China [54] reported increasing fosfomycin resistance among VREfm, frequently associated with fos genes, consistent with our observation of fosXCC/fosI in multiple isolates.Three VREfm genomes (G239-ST262-CT7004, G384-ST17-CT10029, and G1768-ST17-CT10027) carried genes associated with trimethoprim resistance (dfrF and dfrG). Linezolid is currently FDA-approved for VRE infection treatment [34]. Linezolid resistance is a significant concern. Fortunately, linezolid-resistant genes (i.e., cfr, optrA, and poxtA) were not detected in this study, supporting the linezolid phenotypic antimicrobial susceptibility results. Numerous virulence genes, such as those involved in biofilm formation, adhesion, and host cell invasion, can be expressed by Enterococci [55]. The genomic profiles of VREfm isolates in this study demonstrate the association between sequence types and resistance gene patterns. ST262 and ST787 stood out with the highest resistance gene diversity. These sequence types may pose a greater risk of therapeutic failure due to their potential for multidrug resistance. In contrast, ST17 remains the dominant strain with a stable resistance profile, reflecting endemic hospital adaptation.
Genome analysis from six representative strains identified several virulence genes with adhesin protein (i.e., acm, ebpA, ebpB, ebpC, srtC, ecbA, efmA, esp, scm, and sgrA), capsule (cpsA/uppS and cpsB/cdsA), biofilm formation (bopD), and hyaluronidase enzyme (hylE). A previous report stated that the cpsA and cpsB genes are common in E. faecium, and the esp and hyl genes are exclusively present in HA clade strains, including most strains responsible for human infections [56]. The hylE gene responsible for intestinal colonization has been detected in ampicillin-resistant E. faecium ST17 and VREfm strains in hospitals worldwide [57]. Characterizing plasmids and mobile genetic elements is essential for understanding phenotypic traits such as the ability to colonize hosts, enhance bacterial virulence, and acquire antimicrobial resistance. These elements play a critical role in the diversification of Enterococci and appear to contribute to their adaptation in hospital environments [58]. Eleven types of plasmid replicons were identified in the analyzed genomes, with rep11a and repUS15 being the most common replicons in representative VREfm genomes, and some contained rep14a, rep17, rep1, rep2, repUS43, rep22, rep17, repUS7, and rep18b. One isolate from this study (G293-ST787) exhibited the repUS43 plasmid carrying the tetM and tetL genes. The findings of a previous study indicated that the tetM gene is often associated with the chromosomally integrated repUS43 locus [59]. Six IS families were identified in the analyzed genomes. All six representative VREfm genomes contained IS16, a specific marker for hospital-associated strains of E. faecium [60], whereas some genomes also included ISEfa5, ISLgar5, ISEfa11, IS256, and ISEfm2. These mobile genetic elements may play roles in the antibiotic resistance, adaptation, and genome plasticity of VRE. The genomic characterization of vancomycin-resistant Enterococcus (VRE) provides valuable insights into the genetic features, resistance mechanisms, and clonal lineages of VRE strains circulating in our hospital, thereby supporting local surveillance and infection control strategies. However, a limitation of this comparative analysis is the uneven distribution of sequence types among the whole-genome sequenced isolates. While the majority of isolates belonged to ST17, only a single representative was available for ST262, ST202, ST80, and ST787. This limited sample size for non-ST17 sequence types may restrict the generalizability of resistance and virulence gene comparisons across different lineages and may not fully capture the genetic diversity within those STs.
This study has several key strengths. First, it provides comprehensive characterization of VREfm by combining phenotypic antimicrobial susceptibility testing with molecular analyses, including MLST, resistance gene profiling, and virulence gene detection, offering an in-depth view of circulating strains. Second, the work is based on clinical isolates from a tertiary-care referral hospital, making the findings directly applicable to real-world patient care, infection control, and antimicrobial stewardship. Third, the study identifies the dominant clonal lineage (CC17/ST17) and describes the population structure and associated resistance/virulence profiles, contributing important baseline molecular data for Thailand. Finally, the study contributes valuable local genomic data for VREfm, supporting infection control and antimicrobial stewardship in tertiary-care hospital settings.
Conclusions
This study revealed that the vanA gene primarily mediates vancomycin resistance in the study strains. In terms of virulence, the strains carried at least one key virulence gene, esp, which encodes an adhesin protein associated with enhanced colonization and persistence. Notably, esp was frequently co-harbored with the hyl gene, which encodes hyaluronidase—an enzyme that facilitates tissue invasion. These findings indicate a potential link between virulence factors and antimicrobial resistance mechanisms. Effective infection control practices and active surveillance measures should be continuously implemented. Molecular techniques can successfully identify antibiotic-resistant genes, thereby enabling better monitoring and management of VRE infections in hospitals. Furthermore, this study provides an overview of the genomic characteristics of six representative VREfm isolates, examining various antibiotic resistance genes, virulence genes, and mobile genetic elements that may contribute to the spread of antimicrobial resistance. These factors enhance genetic diversity and improve adaptation in hospital environments.
Supporting information
S1 Table. List of primers and PCR conditions used in this study.
https://doi.org/10.1371/journal.pone.0343967.s001
(DOCX)
S1 Fig. The phylogenetic tree illustrates the relationships of the nucleotide sequences of seven concatenated housekeeping genes (i.e., atpA, ddl, gdh, purK, gyd, pstS, and adk) from 52 VREfm isolates.
These isolates were classified based on the following STs: ST17 (•), ST202 (•), ST262 (•), ST80 (•), and ST787(•).
https://doi.org/10.1371/journal.pone.0343967.s002
(TIFF)
S2 Table. Genome characteristics of six representative VREfm strains.
https://doi.org/10.1371/journal.pone.0343967.s003
(PDF)
Acknowledgments
The authors would like to thank the Division of Central Laboratory and Blood Bank, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, for collecting bacterial strains and maintaining a database. We also thank the Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, for providing research equipment for this study.
References
- 1.
Kristich CJ, Rice LB, Arias CA. Enterococcal infection-treatment and antibiotic resistance. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug resistant infection. Boston; 2014.
- 2. Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of Enterococci. Microbiol Spectr. 2019;7(4).
- 3. Biswas PP, Dey S, Sen A, Adhikari L. Molecular characterization of virulence genes in vancomycin-resistant and vancomycin-sensitive enterococci. J Glob Infect Dis. 2016;8(1):16–24.
- 4. Kubašová I, Strompfová V, Lauková A. Safety assessment of commensal enterococci from dogs. Folia Microbiol (Praha). 2017;62(6):491–8. pmid:28316009
- 5. Nielsen HV, Guiton PS, Kline KA, Port GC, Pinkner JS, Neiers F, et al. The metal ion-dependent adhesion site motif of the Enterococcus faecalis EbpA pilin mediates pilus function in catheter-associated urinary tract infection. mBio. 2012;3(4):e00177-12. pmid:22829678
- 6. Puchter L, Chaberny IF, Schwab F, Vonberg R-P, Bange F-C, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018;7:1. pmid:29312658
- 7. Billington EO, Phang SH, Gregson DB, Pitout JDD, Ross T, Church DL, et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis. 2014;26:76–82. pmid:24813873
- 8. Van Tyne D, Gilmore MS. Friend turned foe: evolution of enterococcal virulence and antibiotic resistance. Annu Rev Microbiol. 2014;68:337–56. pmid:25002090
- 9. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266–78. pmid:22421879
- 10. Guzman Prieto AM, van Schaik W, Rogers MRC, Coque TM, Baquero F, Corander J, et al. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? Front Microbiol. 2016;7:788. pmid:27303380
- 11. Codelia-Anjum A, Lerner LB, Elterman D, Zorn KC, Bhojani N, Chughtai B. Enterococcal urinary tract infections: a review of the pathogenicity, epidemiology, and treatment. Antibiotics (Basel). 2023;12(4).
- 12. García-Solache M, Rice LB. The Enterococcus: a model of adaptability to its environment. Clin Microbiol Rev. 2019;32(2):e00058-18. pmid:30700430
- 13. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13(4):686–707. pmid:11023964
- 14. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27. pmid:29276051
- 15. Gastmeier P, Schröder C, Behnke M, Meyer E, Geffers C. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother. 2014;69(6):1660–4. pmid:24615816
- 16. Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect. 2020;9(1):1180–93. pmid:32498615
- 17.
Thailand National Antimicrobial Resistance Surveillance Center. NARST Dashboard [Internet]. Department of Medical Sciences, Ministry of Public Health, Thailand; 2026 [cited 2026 Jan 7]. Available from: https://narst.dmsc.moph.go.th/Dashborad
- 18. Alcock BP, Huynh W, Chalil R, Smith KW, Raphenya AR, Wlodarski MA, et al. CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 2023;51(D1):D690–D9.
- 19. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75(12):3491–500. pmid:32780112
- 20. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014;58(7):3895–903. pmid:24777092
- 21. Johansson MHK, Bortolaia V, Tansirichaiya S, Aarestrup FM, Roberts AP, Petersen TN. Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder. J Antimicrob Chemother. 2021;76(1):101–9. pmid:33009809
- 22. Malberg Tetzschner AM, Johnson JR, Johnston BD, Lund O, Scheutz F. In silico genotyping of Escherichia coli isolates for extraintestinal virulence genes by use of whole-genome sequencing data. J Clin Microbiol. 2020;58(10):e01269-20. pmid:32669379
- 23.
Agudelo Higuita NI, Huycke MM. Enterococcal disease, epidemiology, and implications for treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug resistant infection. Boston; 2014.
- 24. Zaheer R, Cook SR, Barbieri R, Goji N, Cameron A, Petkau A, et al. Surveillance of Enterococcus spp. reveals distinct species and antimicrobial resistance diversity across a One-Health continuum. Sci Rep. 2020;10(1):3937. pmid:32127598
- 25. Murray BE. Diversity among multidrug-resistant enterococci. Emerg Infect Dis. 1998;4(1):37–47. pmid:9452397
- 26. Saengsuwan P, Singkhamanan K, Madla S, Ingviya N, Romyasamit C. Molecular epidemiology of vancomycin-resistant Enterococcus faecium clinical isolates in a tertiary care hospital in southern Thailand: a retrospective study. PeerJ. 2021;9:e11478. pmid:34055492
- 27. Chopjitt P, Boueroy P, Jenjaroenpun P, Wongsurawat T, Hatrongjit R, Kerdsin A, et al. Genomic characterization of vancomycin-resistant Enterococcus faecium clonal complex 17 isolated from urine in tertiary hospitals in Northeastern Thailand. Front Microbiol. 2024;14:1278835. pmid:38312503
- 28. Health Policy and Systems Research on Antimicrobial Resistance Network. Thai AMR Watch [Internet]. [cited 2026 Jan 8]. Available from: https://www.thaiamrwatch.net
- 29. Shrestha S, Kharel S, Homagain S, Aryal R, Mishra SK. Prevalence of vancomycin-resistant enterococci in Asia-A systematic review and meta-analysis. J Clin Pharm Ther. 2021;46(5):1226–37. pmid:33630382
- 30. Buetti N, Wassilew N, Rion V, Senn L, Gardiol C, Widmer A, et al. Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey. Antimicrob Resist Infect Control. 2019;8:16. pmid:30675343
- 31. Zalipour M, Esfahani BN, Havaei SA. Phenotypic and genotypic characterization of glycopeptide, aminoglycoside and macrolide resistance among clinical isolates of Enterococcus faecalis: a multicenter based study. BMC Res Notes. 2019;12(1):292. pmid:31133071
- 32. Ricaurte JC, Boucher HW, Turett GS, Moellering RC, Labombardi VJ, Kislak JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect. 2001;7(1):17–21. pmid:11284938
- 33. Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 2005;245(2):195–203. pmid:15837373
- 34. Miller WR, Murray BE, Rice LB, Arias CA. Resistance in vancomycin-resistant enterococci. Infect Dis Clin North Am. 2020;34(4):751–71. pmid:33131572
- 35. Fiedler S, Bender JK, Klare I, Halbedel S, Grohmann E, Szewzyk U, et al. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). J Antimicrob Chemother. 2016;71(4):871–81. pmid:26682961
- 36. Ben Said L, Klibi N, Lozano C, Dziri R, Ben Slama K, Boudabous A, et al. Diversity of enterococcal species and characterization of high-level aminoglycoside resistant enterococci of samples of wastewater and surface water in Tunisia. Sci Total Environ. 2015;530–531:11–7. pmid:26026404
- 37. Comerlato CB, Resende MCC de, Caierão J, d’Azevedo PA. Presence of virulence factors in Enterococcus faecalis and Enterococcus faecium susceptible and resistant to vancomycin. Mem Inst Oswaldo Cruz. 2013;108(5):590–5. pmid:23903974
- 38. Neumann B, Bender JK, Maier BF, Wittig A, Fuchs S, Brockmann D, et al. Comprehensive integrated NGS-based surveillance and contact-network modeling unravels transmission dynamics of vancomycin-resistant enterococci in a high-risk population within a tertiary care hospital. PLoS One. 2020;15(6):e0235160. pmid:32579600
- 39. Sassi M, Guerin F, Zouari A, Beyrouthy R, Auzou M, Fines-Guyon M. Emergence of optrA-mediated linezolid resistance in enterococci from France, 2006-16. J Antimicrob Chemother. 2019;74(6):1469–72.
- 40. Lee T, Pang S, Stegger M, Sahibzada S, Abraham S, Daley D, et al. A three-year whole genome sequencing perspective of Enterococcus faecium sepsis in Australia. PLoS One. 2020;15(2):e0228781. pmid:32059020
- 41. Wongnak K, Pattanachaiwit S, Rattanasirirat W, Limsrivanichakorn S, Kiratisin P, Assanasen S, et al. First characterization of Tn1546-like structures of vancomycin-resistant Enterococcus faecium Thai isolates. J Infect Chemother. 2021;27(7):991–8. pmid:33663929
- 42. Sun H-L, Liu C, Zhang J-J, Zhou Y-M, Xu Y-C. Molecular characterization of vancomycin-resistant enterococci isolated from a hospital in Beijing, China. J Microbiol Immunol Infect. 2019;52(3):433–42. pmid:30827858
- 43. Cho SY, Park YJ, Cho H, Park DJ, Yu JK, Oak HC, et al. Comparison of Enterococcus faecium bacteremic isolates from hematologic and non-hematologic patients: differences in antimicrobial resistance and molecular characteristics. Ann Lab Med. 2018;38(3):226–34. pmid:29401557
- 44. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother. 2011;66(4):713–21.
- 45. Quiñones D, Aung MS, Sousa Martins JP, Urushibara N, Kobayashi N. Genetic characteristics of VanA-type vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in Cuba. New Microbes New Infect. 2017;21:125–7. pmid:29348921
- 46. Brilliantova AN, Kliasova GA, Mironova AV, Tishkov VI, Novichkova GA, Bobrynina VO, et al. Spread of vancomycin-resistant Enterococcus faecium in two haematological centres in Russia. Int J Antimicrob Agents. 2010;35(2):177–81. pmid:20005678
- 47. Al Rubaye M, Janice J, Bjørnholt JV, Kacelnik O, Haldorsen BC, Nygaard RM, et al. The population structure of vancomycin-resistant and -susceptible Enterococcus faecium in a low-prevalence antimicrobial resistance setting is highly influenced by circulating global hospital-associated clones. Microb Genom. 2023;9(12):001160. pmid:38112685
- 48. Caplunik-Pratsch A, Kieninger B, Donauer VA, Brauer JM, Meier VMK, Seisenberger C, et al. Introduction and spread of vancomycin-resistant Enterococcus faecium (VREfm) at a German tertiary care medical center from 2004 until 2010: a retrospective whole-genome sequencing (WGS) study of the molecular epidemiology of VREfm. Antimicrob Resist Infect Control. 2024;13(1):20. pmid:38355509
- 49. Zhou W, Zhou H, Sun Y, Gao S, Zhang Y, Cao X, et al. Characterization of clinical enterococci isolates, focusing on the vancomycin-resistant enterococci in a tertiary hospital in China: based on the data from 2013 to 2018. BMC Infect Dis. 2020;20(1):356. pmid:32517758
- 50. Costa Y, Galimand M, Leclercq R, Duval J, Courvalin P. Characterization of the chromosomal aac(6’)-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother. 1993;37(9):1896–903. pmid:8239603
- 51. Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016:2082693. pmid:27366158
- 52. Wenzler E, Ellis-Grosse EJ, Rodvold KA. Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers. Antimicrob Agents Chemother. 2017;61(9).
- 53. Abbott IJ, van Gorp E, van der Meijden A, Wijma RA, Meletiadis J, Roberts JA, et al. Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic in vitro model. Antimicrob Agents Chemother. 2020;64(6):e00342-20. pmid:32253214
- 54. Zhang X, Bi W, Chen L, Zhang Y, Fang R, Cao J. Molecular mechanisms and epidemiology of fosfomycin resistance in enterococci isolated from patients at a teaching hospital in China, 2013-2016. J Glob Antimicrob Resist. 2020;20:191–6.
- 55. Anderson AC, Jonas D, Huber I, Karygianni L, Wölber J, Hellwig E, et al. Enterococcus faecalis from food, clinical specimens, and oral sites: prevalence of virulence factors in association with biofilm formation. Front Microbiol. 2016;6:1534. pmid:26793174
- 56. Qin X, Galloway-Peña JR, Sillanpaa J, Roh JH, Nallapareddy SR, Chowdhury S, et al. Complete genome sequence of Enterococcus faecium strain TX16 and comparative genomic analysis of Enterococcus faecium genomes. BMC Microbiol. 2012;12:135. pmid:22769602
- 57. Coque TM, Willems RJL, Fortún J, Top J, Diz S, Loza E, et al. Population structure of Enterococcus faecium causing bacteremia in a Spanish university hospital: setting the scene for a future increase in vancomycin resistance? Antimicrob Agents Chemother. 2005;49(7):2693–700. pmid:15980338
- 58. Freitas AR, Tedim AP, Novais C, Ruiz-Garbajosa P, Werner G, Laverde-Gomez JA, et al. Global spread of the hyl(Efm) colonization-virulence gene in megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster. Antimicrob Agents Chemother. 2010;54(6):2660–5. pmid:20385861
- 59. Sharon BM, Arute AP, Nguyen A, Tiwari S, Bonthu SSR, Hulyalkar NV. Functional and genetic adaptations contributing to Enterococcus faecalis persistence in the female urinary tract. bioRxiv. 2023.
- 60. Werner G, Fleige C, Geringer U, van Schaik W, Klare I, Witte W. IS element IS16 as a molecular screening tool to identify hospital-associated strains of Enterococcus faecium. BMC Infect Dis. 2011;11:80. pmid:21453466